Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Phase 1 Completed 24 enrolled Regeneron Pharmaceuticals

RandomizedSingle-groupQuadruple-blindTreatment

This study is a pilot, ascending dose, multi-center, randomized, double blind, placebo controlled, pediatric study conducted in three phases.

Evaluation	Drug	Modality	Dose	Route
Subject	Rilonacept	Protein / enzyme biologic	2.2 mg/kg	Subcutaneous
Subject	Rilonacept	Protein / enzyme biologic	4.4 mg/kg	Subcutaneous